Patients taking Novo Nordisk's Wegovy obesity treatment maintained an average of 10% weight loss after four years, ...
Presented at this week’s European Congress on Obesity, the two studies also demonstrate that Novo Nordisk’s Wegovy ...
The results shed light on the long-term effects of Wegovy, and could boost Novo Nordisk's case to insurers and governments to ...
Two new studies published on ... the active ingredient in Wegovy and Novo Nordisk’s diabetes drug Ozempic, on a weekly basis. “This degree of weight loss in such a large and diverse population ...
Novo Nordisk's (NVO) obesity therapy Wegovy cut adverse kidney-related events by 22% in obese and overweight individuals in a ...
Researchers highlighted on Monday that certain genes may help identify patients with obesity who are most likely to respond ...
Novo Nordisk is already assessing semaglutide’s effects in liver disease linked to obesity — metabolic dysfunction-associated ...
Patients taking Novo Nordisk's obesity drug Wegovy maintained an average ... a patient's heart health through methods beyond weight loss, the study authors concluded. Notably, the weight loss ...
Patients taking Novo Nordisk's obesity drug Wegovy maintained an average of 10% weight loss for up to four years, according to a new analysis from the ... Participants were not required to track diet ...
Amid the growing popularity of drugs used for weight loss like Ozempic, Wegovy, Mounjaro and Zepbound, one question has ...
LONDON, May 14 (Reuters) - Patients taking Novo Nordisk's Wegovy obesity treatment ... was less than the average of 15% weight loss in earlier Wegovy obesity studies before the drug was launched ...